Please assess the completion status of the following clinical trial:

Trial Title: Ethiopia Malaria Therapeutic Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Slide-confirmed infection with P. falciparum, with parasitemia of 1,000-100,000 asexual forms/ μl or slide confirmed infection with P. vivax with \> 250 asexual forms/ μl~* Lives within 20 km of the enrolling health facility~* Weight ≥ 5.0 kg~* Axillary temperature ≥ 37.5º C or history of fever during the previous 24 or 48 hours for P. falciparum and P. vivax infection, respectively~* Patient or caregiver agrees to all blood draws and return visits.~Exclusion Criteria:~* General danger signs or symptoms of severe malaria~* Signs or symptoms of severe malnutrition, defined as weight-for-age ≤ 3 standard deviations below the mean (NCHS/WHO normalized reference values;~* Slide confirmed infection with any other Plasmodium spp. besides falciparum/vivax or mixed plasmodium infection~* Severe anemia, defined as Hg \< 5 g/dl~* Known hypersensitivity to any of the drugs being evaluated~* Presence of febrile conditions caused by diseases other than malaria~* Serious or chronic medical condition (cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS)~* Pregnant or breastfeeding women.~* Children weighing less than 5 kilograms.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroquine-P. vivax (Type: EXPERIMENTAL): P. vivax randomized to receive chloroquine 3-day regimen
- Artemether-Lumefantrine: P. vivax (Type: EXPERIMENTAL): None
- Artemether-lumefantrine: P. falciparum (Type: EXPERIMENTAL): administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).